Возможности и перспективы отмены глюкокортикоидов при системной красной волчанке
https://doi.org/10.14412/1996-7012-2020-1-6-11
Аннотация
Об авторах
С. К. СоловьевРоссия
115522, Москва, Каширское шоссе, 34А
Е. А. Асеева
Россия
115522, Москва, Каширское шоссе, 34А
Е. Л. Насонов
Россия
115522, Москва, Каширское шоссе, 34А;
кафедра внутренних, профессиональных болезней и ревматологии, 119991, Москва, ул. Трубецкая, 8, стр. 2
А. М. Лила
Россия
115522, Москва, Каширское шоссе, 34А;
кафедра ревматологии, 125993, Москва, ул. Баррикадная, 2/1, стр. 1
Г. М. Койлубаева
Кыргызстан
720040, Бишкек, ул. Тоголока Молдо, 3
Литература
1. Насонов ЕЛ. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017.
2. Soffer LJ, Barder R. Corticotropin and cortisone in acute disseminated lupus erythematosus; results of long-term use. J Am Med Assoc. 1952 Jul 12;149(11):1002-8. doi: 10.1001/jama.1952.02930280024007
3. Mosca M, Tani C, Carli L, et al. Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol. 2011;29 (5 Suppl 68):S126-9.
4. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1955-9.
5. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43:1801-8. doi: 10.1002/1529-0131(200008)43:83.0.CO;2-O
6. Dixon WG, Abrahamowicz M, Beauchamp M-E, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012;71: 1128-33. doi: 10.1136/annrheumdis-2011-200702
7. Bruce IN. 'Not only… but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology. 2005;44: 1492-502. doi: 10.1093/rheumatology/kei142
8. Bhangle SD, Kramer N, Rosenstein ED. Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int. 2013;33:1923-32. doi: 10.1007/s00296-013-2750-z
9. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016 Oct;12(10):605-20. doi: 10.1038/nrrheum.2016.137
10. Barber MRW, Clarke AE. Socioeconomic consequences of systemic lupus erythematosus. Curr Opin Rheumatol. 2017 Sep;29(5):480-5. doi: 10.1097/BOR.0000000000000416
11. Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019 Jun 8;393(10188):2332-43. doi: 10.1016/S0140-6736(19)30237-5
12. Dö rner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393:2344-58. doi: 10.1016/S0140-6736(19)30546-X
13. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus rythematosus: recommendations from an international Task Force. Ann Rheum Dis. 2014;73:958-67. doi: 10.1136/annrheumdis2013-205139
14. Соловьев СК, Асеева ЕА, Зоткин ЕГ и др. Проблемы низкой активности и ремиссии при системной красной волчанке Научно-практическая ревматология. 2019; 57(2):218-21. doi: 10.14412/1995-4484-2019-218-221.
15. Moroni G, Longhi S, Giglio E, et al. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol. 2013;31:S75-81.
16. Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant. 2006;21:1541-8. doi: 10.1093/ndt/gfk073
17. Moroni G, Gatto M, Raffiotta F, et al. Can we withdraw immunosuppressants in patients with lupus nephritis in remission? an expert debate. Autoimmun Rev. 2018;17:11-8. doi: 10.1016/j.autrev.2017.11.003
18. Mosca M, Tani C, Aringer M. Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal? Clin Exp Rheumatol. 2013;31(4 Suppl 78):S71-4.
19. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League against rheumatism and European renal Association – European dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771-82. doi: 10.1136/annrheumdis-2012-201940
20. Van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international Task Force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017;76:554-61. doi: 10.1136/annrheumdis-2016-209519
21. Ngamjanyaporn P, McCarthy EM, Sergeant JC, et al. Clinicians approaches to management of background treatment inpatients with SLE in clinical remission: results of an international observational survey. Lupus Sci Med. 2017;4:e000173. doi: 10.1136/lupus-2016-000173
22. Tani C, Elefante E, Signorini V, et al. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. RMD Open. 2019;5:e000916. doi: 10.1136/rmdopen2019-000916
23. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75:1615-21. doi: 10.1136/annrheumdis-2015-207726
24. Асеева ЕА, Дубиков АИ, Левашева ЛА и др. Регистр пациентов с системной красной волчанкой, Евразийская когорта (РЕНЕССАНС). Научно-практическая ревматология. 2016;54(5):520-6. doi: 10.14412/1995-4484-2016-520-526.
25. Zen M, Gatto M, Nalotto L, et al. The management of systemic lupus Erythematosus (SLE) patients in Remission. IMAJ. 2017;19:454-8.
26. Steiman AJ, Urowitz MB, Ibanez D, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol. 2014;41(9):1808-16. doi: 10.3899/jrheum.131137
27. Medeiros MM, Bezerra MC, Braga FN, et al. Clinical and immunological aspects and outcome of a Brazilian cohort of 414 patients with systemic lupus erythematosus (SLE): comparison between childhood-onset, adultonset, and late-onset SLE. Lupus. 2016; 25(4):355-63. doi: 10.1177/0961203315606983
28. Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol. 2005 Aug;32(8): 1467-72.
29. Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013 Aug;72(8):1280-6. doi: 10.1136/annrheumdis-2012-202844
30. Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 2007 Mar;71(6):491-5. doi: 10.1038/sj.ki.5002118
31. Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2017;4:e000182. doi: 10.1136/lupus-2016-000182